Loading...
Loading...
IMMX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 24.3K |
| Gross Profit | -24.3K |
| Operating Expense | 4,702.5K |
| Operating I/L | -4,702.5K |
| Other Income/Expense | 306.9K |
| Interest Income | 306.9K |
| Pretax | -4,395.6K |
| Income Tax Expense | 10.3K |
| Net Income/Loss | -4,392.9K |
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing tissue-specific therapeutics for oncology and inflammation. The company's revenue model is based on the development and commercialization of its lead products, including IMX-110, IMX-111, and IMX-120, which are targeted at treating soft tissue sarcoma, solid tumors, colorectal cancers, ulcerative colitis, and severe Crohn's disease. Additionally, Immix Biopharma has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab, further expanding its potential revenue streams.
